Keyword: UCB

UCB, which recently paid $2.5 billion for an autoimmune drug candidate, will build a $333 million facility and staff it with 150 workers.

We may be focusing on our forecasts for the year ahead with today's issue, but here's some Friday news we thought you shouldn't miss.

UCB has launched a new digital campaign featuring its own employees’ diverse experiences as patients, caregivers and researchers.

After a two-and-a-half-year wait for impulse-control warnings on six dopamine drugs, a watchdog group sued to force FDA action.

A judge questioned the Justice Department's motives for dismissing whistleblower allegations that UCB paid kickbacks to boost Cimzia scripts.

On its second try, Evenity won approval only in postmenopausal women at high risk of bone fracture—and with a boxed warning.

The UCB-sponsored fledgling initiative to create a clinical care pathway for women with IBD who are considering pregnancy gets its first-ever awareness campaign.

UCB's new mobile app is built specifically for Parkinson’s disease with a virtual health assistant named April.

Amgen osteoporosis drug Prolia is working to appeal to menopausal women with a new TV ad, but it's leaving behind its celebrity spokeswoman.

MyHealthTeams specialized social networks are adding pharma-sponsored resource centers with its most recent in spondyloarthritis.